PUBLIC COMPANY
save$BNTXBioNTech SE
$BNTX85.26-0.40%Mainz, DEupdated 14h ago
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
community read0 votes
🐶 often sniffed alongside
top 2pipeline
7
marketed
0
phase 3
3
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(7)
pipeline depth7 products
1Preclinical3Phase 23Phase 3
Phase 3
BNT-113
Recurrent Head And Neck Squamous Cell Carcinoma
Phase 3pumitamig
Non-Small Cell Lung Cancer
Phase 3trastuzumab pamirtecan
Endometrial Cancer
Phase 2BNT-111
Metastatic Melanoma
Phase 2DB-1311
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2sacituzumab drozuntecan
Epithelial Ovarian Cancer
PreclinicalUrinary Tract Infections Program
Urinary Tract Infections
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- phase3ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- phase2A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
- phase3A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
- phase1A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs
- phase1A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
- phase2A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that